✦ LIBER ✦

Open-label use of placebos in the treatment of ADHD: a pilot study

✍ Scribed by A. D. Sandler; J. W. Bodfish

Book ID: 108680777
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 141 KB
Volume: 34
Category: Article
ISSN: 0305-1862
DOI: 10.1111/j.1365-2214.2007.00797.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Children's and parents' perspectives on

Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD

✍ A. Sandler; C. Glesne; G. Geller 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Rituximab in the treatment of dermatomyo

Rituximab in the treatment of dermatomyositis: An open-label pilot study

✍ Todd D. Levine 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Levetiracetam for treatment of premenstr

Levetiracetam for treatment of premenstrual dysphoric disorder: A pilot, open-label study

✍ Zerrin Emel Kayatekin; Alex N. Sabo; Uriel Halbreich 📂 Article 📅 2008 🏛 Springer Vienna 🌐 English ⚖ 98 KB

Duloxetine in the treatment of irritable

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study

✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal

Pilot open-label study of nefazodone in

Pilot open-label study of nefazodone in panic disorder

✍ Alexander Bystritsky; Richard Rosen; Rita Suri; Tanya Vapnik 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Ten patients meeting DSM-IV criteria for non-comorbid panic disorder or panic disorder with agoraphobia were treated in a 12-week open-label, flexible dosage trial of nefazodone. Dosages ranged from 50 to 400 mg per day. Clinical assessment utilized several recently developed scales of panic disorde

Open-label pilot study of levetiracetam

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo